The Cooper Companies, Inc. (NASDAQ:COO) Shares Bought by Centiva Capital LP

Centiva Capital LP raised its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 22.2% in the 4th quarter, HoldingsChannel reports. The fund owned 5,861 shares of the medical device company’s stock after buying an additional 1,066 shares during the quarter. Centiva Capital LP’s holdings in Cooper Companies were worth $539,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in COO. Brevan Howard Capital Management LP boosted its holdings in shares of Cooper Companies by 37.8% in the 4th quarter. Brevan Howard Capital Management LP now owns 14,412 shares of the medical device company’s stock valued at $1,325,000 after buying an additional 3,954 shares in the last quarter. Bridgefront Capital LLC purchased a new stake in shares of Cooper Companies in the 4th quarter valued at about $989,000. Captrust Financial Advisors boosted its position in shares of Cooper Companies by 19.0% in the 4th quarter. Captrust Financial Advisors now owns 4,542 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 726 shares during the period. Castlekeep Investment Advisors LLC acquired a new position in Cooper Companies during the fourth quarter worth approximately $685,000. Finally, Baker Avenue Asset Management LP purchased a new stake in Cooper Companies in the fourth quarter valued at approximately $213,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Stock Down 0.8 %

COO opened at $82.27 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The Cooper Companies, Inc. has a 12 month low of $69.81 and a 12 month high of $112.38. The stock has a market capitalization of $16.45 billion, a P/E ratio of 42.19, a P/E/G ratio of 2.25 and a beta of 1.08. The business has a 50 day simple moving average of $80.54 and a 200-day simple moving average of $91.03.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. On average, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. JPMorgan Chase & Co. reduced their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Citigroup lowered their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Finally, BNP Paribas raised Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Cooper Companies has an average rating of “Moderate Buy” and an average price target of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.